<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02311140</url>
  </required_header>
  <id_info>
    <org_study_id>UKJ-IVA-Nasal</org_study_id>
    <nct_id>NCT02311140</nct_id>
  </id_info>
  <brief_title>Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms</brief_title>
  <acronym>KPNSI</acronym>
  <official_title>Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Innsbruck, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the proposed trial in assessment of effects of Kalydeco™ treatment on sinonasal
      involvement in CF patients with at least one mutation of G551D receiving a new therapy with
      the CFTR potentiator. The focus will be given on changes in epithelial lining fluid
      inflammatory markers from CF upper airways sampled by nasal lavage.

      The program is subdivided into a part A assessing inflammatory markers in NL and sinonasal
      symptoms longitudinally from pre-treatment to months with the new therapy.

      Part B will only be performed in a smaller subgroup and assess inflammatory markers in NL
      every second day in the first month of treatment and then every week until the end of month 3
      with Kalydeco™ therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in concentration of inflammatory markers</measure>
    <time_frame>3 yrs</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco</condition>
  <arm_group>
    <arm_group_label>Cystic Fibrosis patients with G551D mutation</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms</intervention_name>
    <arm_group_label>Cystic Fibrosis patients with G551D mutation</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal lavage
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CF patients with G551D mutation receiving Kalydeco
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  G551D and Kalydeco therapy

        Exclusion Criteria:

          -  no G551D
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jochen G Mainz, PHD, MD</last_name>
    <phone>+493641938425</phone>
    <email>jochen.mainz@med.uni-jena.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jena University Hospital, CF Center</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen G Mainz, MD, PD</last_name>
      <phone>+493641938425</phone>
      <email>jochen.mainz@med.uni-jena.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2014</study_first_submitted>
  <study_first_submitted_qc>December 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>Head of CF Center, Pediatric Pulmonology</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>nasal lavage</keyword>
  <keyword>inflammation</keyword>
  <keyword>Interleukin (IL)-6</keyword>
  <keyword>IL-8</keyword>
  <keyword>pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

